25 XP   0   0   10

Relmada Therapeutics Inc
Buy, Hold or Sell?

Let's analyze Relmada together

I guess you are interested in Relmada Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Relmada Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Relmada Therapeutics Inc

I send you an email if I find something interesting about Relmada Therapeutics Inc.

Quick analysis of Relmada (30 sec.)










What can you expect buying and holding a share of Relmada? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$2.39
Expected worth in 1 year
$0.62
How sure are you?
27.5%

+ What do you gain per year?

Total Gains per Share
$-1.77
Return On Investment
-58.8%

For what price can you sell your share?

Current Price per Share
$3.01
Expected price per share
$2.61 - $3.24
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

1. Valuation of Relmada (5 min.)




Live pricePrice per Share (EOD)

$3.01

Intrinsic Value Per Share

$-26.34 - $-4.30

Total Value Per Share

$-23.95 - $-1.91

2. Growth of Relmada (5 min.)




Is Relmada growing?

Current yearPrevious yearGrowGrow %
How rich?$72m$157.2m-$64.9m-70.3%

How much money is Relmada making?

Current yearPrevious yearGrowGrow %
Making money-$23.5m-$35.9m$12.3m52.3%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Relmada (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#402 / 966

Most Revenue
#858 / 966

Most Profit
#730 / 966

Most Efficient
#225 / 966
3rd party ad coffee SUPPORTERis ad-free.

What can you expect buying and holding a share of Relmada? (5 min.)

Welcome investor! Relmada's management wants to use your money to grow the business. In return you get a share of Relmada.

What can you expect buying and holding a share of Relmada?

First you should know what it really means to hold a share of Relmada. And how you can make/lose money.

Speculation

The Price per Share of Relmada is $3.01. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Relmada.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Relmada, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.39. Based on the TTM, the Book Value Change Per Share is $-0.44 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.70 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Relmada.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.72-24.0%-0.78-26.0%-1.19-39.5%-0.79-26.2%-0.43-14.4%
Usd Book Value Change Per Share-0.44-14.7%-0.44-14.7%-0.70-23.4%0.123.9%0.062.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.44-14.7%-0.44-14.7%-0.70-23.4%0.123.9%0.062.0%
Usd Price Per Share4.65-3.56-15.44-20.93-11.37-
Price to Earnings Ratio-1.61--1.15--3.00--11.24--7.06-
Price-to-Total Gains Ratio-10.54--8.11--21.88--17.50-145.74-
Price to Book Ratio1.95-1.24-2.73-8.13-10.04-
Price-to-Total Gains Ratio-10.54--8.11--21.88--17.50-145.74-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.01
Number of shares332
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.440.12
Usd Total Gains Per Share-0.440.12
Gains per Quarter (332 shares)-146.9539.37
Gains per Year (332 shares)-587.80157.50
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-588-5980157147
20-1176-11860315304
30-1763-17740472461
40-2351-23620630618
50-2939-29500787775
60-3527-35380945932
70-4115-4126011021089
80-4702-4714012601246
90-5290-5302014171403
100-5878-5890015751560

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%4.036.00.010.0%4.045.00.08.2%
Book Value Change Per Share0.04.00.00.0%3.09.00.025.0%6.014.00.030.0%11.029.00.027.5%13.033.03.026.5%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.049.00.0%
Total Gains per Share0.04.00.00.0%3.09.00.025.0%6.014.00.030.0%11.029.00.027.5%13.033.03.026.5%
3rd party ad coffee SUPPORTERis ad-free.

Fundamentals of Relmada

About Relmada Therapeutics Inc

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

Fundamental data was last updated by Penke on 2024-06-19 05:33:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

1.1. Profitability of Relmada Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Relmada earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Relmada to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Relmada Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--168.0%+168.0%
TTM--209.9%+209.9%
YOY--242.3%+242.3%
5Y--401.7%+401.7%
10Y--532.2%+532.2%
1.1.2. Return on Assets

Shows how efficient Relmada is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Relmada to the Biotechnology industry mean.
  • -25.9% Return on Assets means that Relmada generated $-0.26 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Relmada Therapeutics Inc:

  • The MRQ is -25.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -23.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-25.9%TTM-23.1%-2.7%
TTM-23.1%YOY-21.0%-2.2%
TTM-23.1%5Y-21.9%-1.3%
5Y-21.9%10Y-38.8%+17.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-25.9%-11.9%-14.0%
TTM-23.1%-11.9%-11.2%
YOY-21.0%-11.3%-9.7%
5Y-21.9%-13.5%-8.4%
10Y-38.8%-14.9%-23.9%
1.1.3. Return on Equity

Shows how efficient Relmada is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Relmada to the Biotechnology industry mean.
  • -30.3% Return on Equity means Relmada generated $-0.30 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Relmada Therapeutics Inc:

  • The MRQ is -30.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -26.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-30.3%TTM-26.1%-4.2%
TTM-26.1%YOY-23.0%-3.1%
TTM-26.1%5Y-25.6%-0.4%
5Y-25.6%10Y-51.0%+25.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-30.3%-14.2%-16.1%
TTM-26.1%-15.7%-10.4%
YOY-23.0%-14.3%-8.7%
5Y-25.6%-19.2%-6.4%
10Y-51.0%-19.7%-31.3%
3rd party ad coffee SUPPORTERis ad-free.

1.2. Operating Efficiency of Relmada Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Relmada is operating .

  • Measures how much profit Relmada makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Relmada to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Relmada Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--354.6%+354.6%
TTM--225.9%+225.9%
YOY--252.2%+252.2%
5Y--428.3%+428.3%
10Y--531.1%+531.1%
1.2.2. Operating Ratio

Measures how efficient Relmada is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Relmada Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.004-3.004
TTM-3.332-3.332
YOY-3.502-3.502
5Y-5.271-5.271
10Y-6.915-6.915
3rd party ad coffee SUPPORTERis ad-free.

1.3. Liquidity of Relmada Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Relmada is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 6.82 means the company has $6.82 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Relmada Therapeutics Inc:

  • The MRQ is 6.825. The company is very able to pay all its short-term debts. +2
  • The TTM is 9.794. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.825TTM9.794-2.969
TTM9.794YOY11.523-1.729
TTM9.7945Y18.914-9.121
5Y18.91410Y10.406+8.508
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.8253.767+3.058
TTM9.7944.000+5.794
YOY11.5234.905+6.618
5Y18.9145.883+13.031
10Y10.4066.286+4.120
1.3.2. Quick Ratio

Measures if Relmada is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Relmada to the Biotechnology industry mean.
  • A Quick Ratio of 13.42 means the company can pay off $13.42 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Relmada Therapeutics Inc:

  • The MRQ is 13.420. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 18.530. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ13.420TTM18.530-5.110
TTM18.530YOY20.722-2.192
TTM18.5305Y34.217-15.688
5Y34.21710Y17.986+16.231
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ13.4203.054+10.366
TTM18.5303.506+15.024
YOY20.7224.756+15.966
5Y34.2175.757+28.460
10Y17.9866.338+11.648
3rd party ad coffee SUPPORTERis ad-free.

1.4. Solvency of Relmada Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Relmada assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Relmada to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.15 means that Relmada assets are financed with 14.6% credit (debt) and the remaining percentage (100% - 14.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Relmada Therapeutics Inc:

  • The MRQ is 0.146. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.109. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.146TTM0.109+0.037
TTM0.109YOY0.089+0.020
TTM0.1095Y0.106+0.004
5Y0.10610Y0.593-0.487
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1460.330-0.184
TTM0.1090.342-0.233
YOY0.0890.287-0.198
5Y0.1060.368-0.262
10Y0.5930.382+0.211
1.4.2. Debt to Equity Ratio

Measures if Relmada is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Relmada to the Biotechnology industry mean.
  • A Debt to Equity ratio of 17.2% means that company has $0.17 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Relmada Therapeutics Inc:

  • The MRQ is 0.172. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.124. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.172TTM0.124+0.048
TTM0.124YOY0.098+0.026
TTM0.1245Y0.126-0.003
5Y0.12610Y1.028-0.902
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1720.365-0.193
TTM0.1240.415-0.291
YOY0.0980.370-0.272
5Y0.1260.443-0.317
10Y1.0280.476+0.552
3rd party ad coffee SUPPORTERis ad-free.

2. Market Valuation of Relmada Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Relmada generates.

  • Above 15 is considered overpriced but always compare Relmada to the Biotechnology industry mean.
  • A PE ratio of -1.61 means the investor is paying $-1.61 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Relmada Therapeutics Inc:

  • The EOD is -1.040. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.607. Based on the earnings, the company is expensive. -2
  • The TTM is -1.152. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.040MRQ-1.607+0.567
MRQ-1.607TTM-1.152-0.454
TTM-1.152YOY-3.003+1.851
TTM-1.1525Y-11.237+10.085
5Y-11.23710Y-7.062-4.176
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.040-2.341+1.301
MRQ-1.607-2.997+1.390
TTM-1.152-2.882+1.730
YOY-3.003-3.553+0.550
5Y-11.237-6.262-4.975
10Y-7.062-6.288-0.774
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Relmada Therapeutics Inc:

  • The EOD is -1.742. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.691. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.270. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.742MRQ-2.691+0.949
MRQ-2.691TTM-2.270-0.420
TTM-2.270YOY-4.697+2.426
TTM-2.2705Y-19.695+17.425
5Y-19.69510Y-12.758-6.938
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.742-2.932+1.190
MRQ-2.691-3.739+1.048
TTM-2.270-3.776+1.506
YOY-4.697-4.917+0.220
5Y-19.695-7.942-11.753
10Y-12.758-8.503-4.255
3rd party ad coffee SUPPORTERis ad-free.
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Relmada is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.95 means the investor is paying $1.95 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Relmada Therapeutics Inc:

  • The EOD is 1.261. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.947. Based on the equity, the company is underpriced. +1
  • The TTM is 1.244. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.261MRQ1.947-0.687
MRQ1.947TTM1.244+0.703
TTM1.244YOY2.730-1.486
TTM1.2445Y8.128-6.884
5Y8.12810Y10.044-1.916
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.2611.843-0.582
MRQ1.9472.249-0.302
TTM1.2442.301-1.057
YOY2.7302.412+0.318
5Y8.1283.782+4.346
10Y10.0444.212+5.832
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Relmada Therapeutics Inc.

3.1. Institutions holding Relmada Therapeutics Inc

Institutions are holding 49.355% of the shares of Relmada Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-03-31Vanguard Group Inc4.16480.00011256705-54100-4.1272
2024-03-31Deep Track Capital, LP4.10960.16521240034-804473-39.348
2024-03-31Vestal Point Capital LP3.97690.461512000001085000943.4783
2024-03-31Acadian Asset Management LLC3.91460.01911181186-1639-0.1386
2024-03-31Parsons Capital Management Inc3.22630.3098973520236792.4929
2024-03-31Opaleye Management Inc2.51540.7692759000-118000-13.455
2024-03-31Palo Alto Investors, LLC2.42720.384173240000
2024-03-31Franklin Resources Inc2.08870.00096302516302510
2024-03-31BlackRock Inc1.91620.000157818854450.9507
2024-03-31Millennium Management LLC1.13160.000734145014254971.6683
2024-03-31Two Sigma Advisers, LLC1.08110.0035326200-2100-0.6397
2024-03-31Geode Capital Management, LLC0.84870.0001256087126745.2068
2024-03-31Two Sigma Investments LLC0.75240.0025227039-75705-25.0063
2024-03-31Deutsche Bank AG0.74520.000522484600
2024-03-31Bank of America Corp0.69790.0001210576-55-0.0261
2024-03-31Marshall Wace Asset Management Ltd0.68890.00152078705434535.3981
2024-03-31Bridgeway Capital Management, LLC0.64880.01861957772570015.1108
2024-03-31Guild Investment Management Inc0.6331.1351191000-21100-9.9481
2024-03-31Group One Trading, LP0.61090.00331843382591116.3552
2024-03-31JPMorgan Chase & Co0.58320.0001175978157182836.2524
Total 36.76143.27611092445+1085564+9.8%

3.2. Funds holding Relmada Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-04-30Vanguard Total Stock Mkt Idx Inv2.82330.000285191600
2024-04-30Franklin Biotechnology Discv A(acc)USD1.85420.125155950013760032.6144
2024-04-30Vanguard Institutional Extnd Mkt Idx Tr1.17190.001335362500
2024-04-30Franklin Biotechnology Discovery A0.91370.11472757007070034.4878
2024-02-29Horizons Psychedelic Stock ETF0.752417.3972227040-36130-13.7288
2024-04-30Fidelity Extended Market Index0.45660.0014137776-1249-0.8984
2024-03-31Bridgeway Ultra-Small Company0.38070.60081148772570028.8191
2024-03-31Federated Hermes MDT Small Cap Growth IS0.31820.092296010-3829-3.8352
2024-03-31Federated Hermes MDT SCG Institutional0.31820.092196010-3829-3.8352
2024-05-31AdvisorShares Psychedelics ETF0.25533.52057702200
2024-03-31Bridgeway Ultra-Small Company Market0.24060.17527260000
2024-05-31Fidelity Enhanced Small Cap ETF0.19350.03035839300
2023-09-30BlackRock Extended Mkt Composite0.1830.00125520900
2024-05-30iShares Micro-Cap ETF0.17970.019654208-752-1.3683
2024-03-31BlackRock Extended Equity Market K0.15970.001548183170.0353
2024-04-30Fidelity Total Market Index0.14450.00024359500
2024-03-31Acadian Global Small-Cap Equity CIT Cl A0.12010.05013623000
2024-04-30Fidelity Series Total Market Index0.10920.00023295300
2024-05-31Avantis US Small Cap Equity ETF0.1050.00913169200
2024-03-31Fidelity VIP Disciplined Small Cap Init0.09780.03382952500
Total 10.777622.26673252064+188228+5.8%

3.3. Insider Transactions

Insiders are holding 8.037% of the shares of Relmada Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-01-31Maged ShenoudaBUY68754.06
2024-01-31Sergio TraversaBUY274604
2024-01-30Chuck EnceBUY145003.87
2024-01-29Maged ShenoudaBUY108003.65
2024-01-29Sergio TraversaBUY315413.71
3rd party ad coffee SUPPORTERis ad-free.

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Relmada Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.441-0.443+0%-0.704+60%0.119-472%0.060-839%
Book Value Per Share--2.3883.061-22%5.212-54%3.779-37%1.922+24%
Current Ratio--6.8259.794-30%11.523-41%18.914-64%10.406-34%
Debt To Asset Ratio--0.1460.109+34%0.089+65%0.106+39%0.593-75%
Debt To Equity Ratio--0.1720.124+39%0.098+76%0.126+36%1.028-83%
Dividend Per Share----0%-0%-0%-0%
Eps---0.723-0.781+8%-1.190+64%-0.787+9%-0.432-40%
Free Cash Flow Per Share---0.432-0.399-8%-0.836+93%-0.494+14%-0.289-33%
Free Cash Flow To Equity Per Share---0.425-0.398-6%-0.711+67%0.145-392%-218.452+51337%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---4.299--------
Intrinsic Value_10Y_min---26.338--------
Intrinsic Value_1Y_max---1.052--------
Intrinsic Value_1Y_min---2.706--------
Intrinsic Value_3Y_max---2.688--------
Intrinsic Value_3Y_min---8.120--------
Intrinsic Value_5Y_max---3.753--------
Intrinsic Value_5Y_min---13.483--------
Market Cap90824342.000-54%140310030.000107495587.500+31%465889648.000-70%631568636.650-78%343227677.790-59%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio1.261-54%1.9471.244+57%2.730-29%8.128-76%10.044-81%
Pe Ratio-1.040+35%-1.607-1.152-28%-3.003+87%-11.237+599%-7.062+339%
Price Per Share3.010-54%4.6503.563+31%15.440-70%20.931-78%11.375-59%
Price To Free Cash Flow Ratio-1.742+35%-2.691-2.270-16%-4.697+75%-19.695+632%-12.758+374%
Price To Total Gains Ratio-6.823+35%-10.541-8.113-23%-21.884+108%-17.500+66%145.736-107%
Quick Ratio--13.42018.530-28%20.722-35%34.217-61%17.986-25%
Return On Assets---0.259-0.231-11%-0.210-19%-0.219-15%-0.388+50%
Return On Equity---0.303-0.261-14%-0.230-24%-0.256-15%-0.510+68%
Total Gains Per Share---0.441-0.443+0%-0.704+60%0.119-472%0.060-839%
Usd Book Value--72046331.00092366490.750-22%157275420.000-54%114018597.200-37%57985520.375+24%
Usd Book Value Change Per Share---0.441-0.443+0%-0.704+60%0.119-472%0.060-839%
Usd Book Value Per Share--2.3883.061-22%5.212-54%3.779-37%1.922+24%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.723-0.781+8%-1.190+64%-0.787+9%-0.432-40%
Usd Free Cash Flow---13036748.000-12047715.000-8%-25219242.000+93%-14913031.100+14%-8718201.350-33%
Usd Free Cash Flow Per Share---0.432-0.399-8%-0.836+93%-0.494+14%-0.289-33%
Usd Free Cash Flow To Equity Per Share---0.425-0.398-6%-0.711+67%0.145-392%-218.452+51337%
Usd Market Cap90824342.000-54%140310030.000107495587.500+31%465889648.000-70%631568636.650-78%343227677.790-59%
Usd Price Per Share3.010-54%4.6503.563+31%15.440-70%20.931-78%11.375-59%
Usd Profit---21828126.000-23574574.000+8%-35904904.000+64%-23759551.600+9%-13881049.450-36%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---0.441-0.443+0%-0.704+60%0.119-472%0.060-839%
 EOD+3 -5MRQTTM+12 -17YOY+15 -145Y+9 -2010Y+11 -18

4.2. Fundamental Score

Let's check the fundamental score of Relmada Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.040
Price to Book Ratio (EOD)Between0-11.261
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than113.420
Current Ratio (MRQ)Greater than16.825
Debt to Asset Ratio (MRQ)Less than10.146
Debt to Equity Ratio (MRQ)Less than10.172
Return on Equity (MRQ)Greater than0.15-0.303
Return on Assets (MRQ)Greater than0.05-0.259
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Relmada Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.117
Ma 20Greater thanMa 503.015
Ma 50Greater thanMa 1003.277
Ma 100Greater thanMa 2004.261
OpenGreater thanClose3.000
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2024-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets84,408
Total Liabilities12,362
Total Stockholder Equity72,046
 As reported
Total Liabilities 12,362
Total Stockholder Equity+ 72,046
Total Assets = 84,408

Assets

Total Assets84,408
Total Current Assets84,365
Long-term Assets43
Total Current Assets
Cash And Cash Equivalents 1,335
Short-term Investments 82,278
Other Current Assets 752
Total Current Assets  (as reported)84,365
Total Current Assets  (calculated)84,365
+/-0
Long-term Assets
Long-term Assets Other 43
Long-term Assets  (as reported)43
Long-term Assets  (calculated)43
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities12,362
Long-term Liabilities0
Total Stockholder Equity72,046
Total Current Liabilities
Accounts payable 5,189
Other Current Liabilities 7,173
Total Current Liabilities  (as reported)12,362
Total Current Liabilities  (calculated)12,362
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock30
Retained Earnings -582,731
Other Stockholders Equity 654,747
Total Stockholder Equity (as reported)72,046
Total Stockholder Equity (calculated)72,046
+/-0
Other
Capital Stock30
Cash and Short Term Investments 83,613
Common Stock Shares Outstanding 30,132
Liabilities and Stockholders Equity 84,408
Net Debt -1,335
Net Invested Capital 72,046
Net Working Capital 72,003



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-31
> Total Assets 
0
0
18
0
10
10
5
20
12
10
25,764
27,847
32,792
27,850
24,393
20,485
16,604
12,718
10,244
7,922
6,225
4,170
2,837
5,614
6,574
4,796
3,048
1,556
3,299
2,604
10,220
8,514
117,136
115,421
134,559
125,599
118,186
103,867
110,769
90,934
223,326
225,808
215,772
187,122
152,905
135,566
122,038
109,149
97,552
84,408
84,40897,552109,149122,038135,566152,905187,122215,772225,808223,32690,934110,769103,867118,186125,599134,559115,421117,1368,51410,2202,6043,2991,5563,0484,7966,5745,6142,8374,1706,2257,92210,24412,71816,60420,48524,39327,85032,79227,84725,7641012205101001800
   > Total Current Assets 
0
0
18
0
10
10
3
18
11
9
25,743
27,818
32,756
27,814
23,968
20,050
15,656
11,775
9,298
6,972
5,296
3,244
2,475
5,265
6,242
4,481
2,738
1,270
3,032
2,330
9,984
8,298
116,940
115,245
134,405
125,465
118,074
103,776
110,700
90,887
223,298
225,779
215,737
187,106
152,870
135,532
122,004
109,101
97,509
84,365
84,36597,509109,101122,004135,532152,870187,106215,737225,779223,29890,887110,700103,776118,074125,465134,405115,245116,9408,2989,9842,3303,0321,2702,7384,4816,2425,2652,4753,2445,2966,9729,29811,77515,65620,05023,96827,81432,75627,81825,743911183101001800
       Cash And Cash Equivalents 
0
0
9
0
8
8
1
15
6
3
25,564
27,391
31,419
26,956
22,470
19,165
15,128
11,349
8,500
6,222
4,714
2,757
1,711
4,685
5,940
4,258
2,239
887
2,427
2,054
9,217
7,850
36,279
12,226
13,824
7,545
2,495
3,804
4,669
11,449
44,443
44,934
37,261
42,524
5,396
28,894
14,469
6,699
4,092
1,335
1,3354,0926,69914,46928,8945,39642,52437,26144,93444,44311,4494,6693,8042,4957,54513,82412,22636,2797,8509,2172,0542,4278872,2394,2585,9404,6851,7112,7574,7146,2228,50011,34915,12819,16522,47026,95631,41927,39125,56436151880900
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
80,165
102,691
120,264
115,594
114,596
98,900
104,399
76,638
167,466
175,716
174,694
141,628
142,927
103,548
104,060
99,569
92,232
82,278
82,27892,23299,569104,060103,548142,927141,628174,694175,716167,46676,638104,39998,900114,596115,594120,264102,69180,16500000000000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
82
0
0
0
263
234
2
0
292
211
62
63
72
66
67
69
309
72
73
82
76
78
79
81
83
85
86
65
42
0
512
0
0
0
0
0
000005120426586858381797876827372309696766726362211292022342630008200000000000000
       Other Current Assets 
0
0
3
0
0
0
0
0
0
0
178
428
1,337
858
63
885
528
427
0
0
579
487
0
369
0
49
0
0
0
0
0
0
424
246
241
2,249
0
991
77
137
0
-4,919
256
0
0
3,090
3,475
0
1,185
752
7521,18503,4753,09000256-4,91901377799102,249241246424000000490369048757900427528885638581,3374281780000000300
   > Long-term Assets 
0
0
0
0
0
0
2
2
1
1
10
29
36
35
425
434
949
942
946
951
930
927
362
348
332
315
310
286
267
273
235
216
196
176
155
134
113
91
69
47
28
28
35
16
35
35
35
48
43
43
43434835353516352828476991113134155176196216235273267286310315332348362927930951946942949434425353629101122000000
       Property Plant Equipment 
0
0
0
0
0
0
2
2
1
1
10
17
24
23
24
22
536
530
531
536
515
512
2
4
4
3
12
11
9
8
7
6
5
4
3
2
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000123456789111234425125155365315305362224232417101122000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
338
322
306
290
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000002903063223380000000000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
12
12
12
401
0
412
413
413
415
415
415
414
360
345
328
311
298
275
258
44
228
210
25
172
152
132
111
90
69
47
28
28
35
16
35
0
35
0
0
0
0003503516352828476990111132152172252102284425827529831132834536041441541541541341341204011212120000000000
> Total Liabilities 
0
0
7
0
12
12
26
34
40
41
26,773
48,570
28,199
25,356
15,583
6,649
4,840
2,513
3,202
2,348
1,550
1,368
1,377
4,149
5,853
7,112
8,561
10,296
1,864
2,130
2,606
2,537
1,458
2,261
2,326
3,389
12,603
12,719
13,917
18,247
15,061
15,409
18,921
20,777
12,469
10,097
10,702
8,422
12,195
12,362
12,36212,1958,42210,70210,09712,46920,77718,92115,40915,06118,24713,91712,71912,6033,3892,3262,2611,4582,5372,6062,1301,86410,2968,5617,1125,8534,1491,3771,3681,5502,3483,2022,5134,8406,64915,58325,35628,19948,57026,7734140342612120700
   > Total Current Liabilities 
0
0
7
0
12
12
26
34
40
41
26,773
48,470
28,099
25,256
15,583
6,649
4,785
2,404
3,061
2,214
1,413
1,229
1,377
3,470
4,575
5,535
5,905
7,103
1,864
2,130
2,606
2,537
1,458
2,261
2,326
3,389
12,603
12,719
13,917
18,247
15,061
15,409
18,921
20,777
12,469
10,097
10,702
8,422
12,195
12,362
12,36212,1958,42210,70210,09712,46920,77718,92115,40915,06118,24713,91712,71912,6033,3892,3262,2611,4582,5372,6062,1301,8647,1035,9055,5354,5753,4701,3771,2291,4132,2143,0612,4044,7856,64915,58325,25628,09948,47026,7734140342612120700
       Short-term Debt 
0
0
0
0
0
0
0
0
840
60
148
148
38
264
264
176
89
614
274
164
110
28
277
194
111
28
285
200
115
29
364
256
110
110
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000011011025636429115200285281111942772811016427461489176264264381481486084000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
634
307
277
873
1,389
1,604
2,942
0
0
29
364
256
110
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000011025636429002,9421,6041,38987327730763400000000000000000000
       Accounts payable 
0
0
7
0
12
12
26
34
40
41
746
625
970
390
835
1,150
1,688
744
1,260
672
307
335
530
351
286
1,092
765
1,019
359
1,080
924
1,267
523
1,103
965
729
8,346
8,083
10,456
12,709
11,193
10,670
7,540
10,426
5,262
4,422
4,854
2,857
3,506
5,189
5,1893,5062,8574,8544,4225,26210,4267,54010,67011,19312,70910,4568,0838,3467299651,1035231,2679241,0803591,0197651,0922863515303353076721,2607441,6881,1508353909706257464140342612120700
       Other Current Liabilities 
0
0
0
0
0
0
0
0
0
0
26,027
47,697
27,091
24,865
14,484
5,323
3,009
1,660
1,527
1,377
996
866
570
2,925
4,178
4,416
4,854
5,884
1,391
1,021
1,318
1,014
825
1,158
1,361
2,661
4,257
4,637
3,461
5,539
3,868
4,739
11,381
10,351
7,207
5,675
5,849
5,565
8,689
7,173
7,1738,6895,5655,8495,6757,20710,35111,3814,7393,8685,5393,4614,6374,2572,6611,3611,1588251,0141,3181,0211,3915,8844,8544,4164,1782,9255708669961,3771,5271,6603,0095,32314,48424,86527,09147,69726,0270000000000
   > Long-term Liabilities 
0
0
7
0
0
12
26
34
40
41
100
100
100
100
1,099
1,326
55
109
141
135
137
139
806
679
1,278
1,576
2,656
3,193
474
1,109
1,289
0
633
1,103
965
729
8,346
8,083
10,456
12,709
11,193
10,670
7,540
10,426
5,262
4,422
0
0
0
0
00004,4225,26210,4267,54010,67011,19312,70910,4568,0838,3467299651,10363301,2891,1094743,1932,6561,5761,278679806139137135141109551,3261,099100100100100414034261200700
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
679
1,278
1,576
2,656
3,193
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000003,1932,6561,5761,27867900000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
100
100
100
0
0
0
55
109
141
134
137
139
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000139137134141109550001001001000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
55
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000550000000000000000
> Total Stockholder Equity
0
0
11
0
-2
-2
-21
-14
-28
-31
-1,109
-20,722
4,593
2,494
8,810
13,836
11,764
10,205
7,042
5,574
4,675
2,802
1,460
1,465
721
-2,316
-5,513
-8,740
1,435
474
7,613
5,977
115,678
113,160
132,233
122,210
105,583
91,147
96,853
72,687
208,265
210,398
196,851
166,345
140,436
125,469
111,336
100,727
85,357
72,046
72,04685,357100,727111,336125,469140,436166,345196,851210,398208,26572,68796,85391,147105,583122,210132,233113,160115,6785,9777,6134741,435-8,740-5,513-2,3167211,4651,4602,8024,6755,5747,04210,20511,76413,8368,8102,4944,593-20,722-1,109-31-28-14-21-2-201100
   Common Stock
0
0
24
0
24
24
24
29
29
29
8
44
54
54
11
11
12
12
12
12
12
12
13
13
13
13
3
13
30
31
10
10
14
15
16
16
16
17
17
18
28
29
30
29
30
30
30
30
30
30
30303030303029302928181717161616151410103130133131313131212121212121111545444829292924242402400
   Retained Earnings Total Equity000-513,735-488,433-462,111000000-201,5300-158,553-141,651-130,5320-115,332-111,662-107,540-104,854-97,724-94,344-90,994-87,792-86,365-85,383-83,750-81,768-80,738-79,097-75,780-73,920-71,4590-76,122-82,165-79,702-85,1570-75-72-570-250000
   Accumulated Other Comprehensive Income 00000000000000-15-14-13-12-11-10-8-7-6-5-4-3-3-2-130-107-83-64-44-160000-300-100000000
   Capital Surplus 
0
0
0
0
0
0
15
15
15
0
64,388
84,240
84,604
84,921
0
85,284
85,672
85,972
86,127
86,299
86,431
86,540
86,831
87,817
88,501
88,666
88,819
88,971
106,259
107,983
119,237
121,299
235,523
243,677
273,868
280,747
0
292,661
0
0
0
0
0
0
602,517
613,872
625,041
0
0
0
000625,041613,872602,517000000292,6610280,747273,868243,677235,523121,299119,237107,983106,25988,97188,81988,66688,50187,81786,83186,54086,43186,29986,12785,97285,67285,284084,92184,60484,24064,3880151515000000
   Treasury Stock00000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
15
15
15
15
54,201
64,388
84,240
84,604
84,921
85,284
85,672
85,972
86,127
86,299
86,431
86,540
86,831
87,817
88,501
88,666
88,828
88,971
106,259
107,983
119,266
121,299
235,523
243,677
273,868
280,747
284,882
292,661
324,918
343,358
513,304
555,182
581,569
590,483
602,517
613,872
625,041
636,434
646,230
654,747
654,747646,230636,434625,041613,872602,517590,483581,569555,182513,304343,358324,918292,661284,882280,747273,868243,677235,523121,299119,266107,983106,25988,97188,82888,66688,50187,81786,83186,54086,43186,29986,12785,97285,67285,28484,92184,60484,24064,38854,20115151515000000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-103,702
Operating Income-103,702-103,702
 
Operating Expense (+$)
Research Development54,807
Selling General Administrative48,895
Selling And Marketing Expenses12,308
Operating Expense103,702116,010
 
Net Interest Income (+$)
Interest Income5,152
Interest Expense-0
Other Finance Cost-0
Net Interest Income5,152
 
Pretax Income (+$)
Operating Income-103,702
Net Interest Income5,152
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-98,792-108,613
EBIT - interestExpense = -207,404
-98,895
-98,792
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-207,404-98,792
Earnings Before Interest and Taxes (EBITDA)-103,702
 
After tax Income (+$)
Income Before Tax-98,792
Tax Provision-0
Net Income From Continuing Ops-98,792-98,792
Net Income-98,792
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses103,702
Total Other Income/Expenses Net4,911-5,152
 

Technical Analysis of Relmada
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Relmada. The general trend of Relmada is BEARISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Relmada's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-71.4%) Bearish trend (71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Relmada Therapeutics Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 3.08 < 3.19 < 3.24.

The bearish price targets are: 2.945 > 2.86 > 2.61.

Tweet this
Relmada Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Relmada Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 2/14.
The longshort score for the Moving Averages is -10/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Relmada Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Relmada Therapeutics Inc. The current macd is -0.08098315.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Relmada price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Relmada. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Relmada price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Relmada Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartRelmada Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Relmada Therapeutics Inc. The current adx is 27.88.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Relmada shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
Relmada Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Relmada Therapeutics Inc. The current sar is 2.83554285.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Relmada Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Relmada Therapeutics Inc. The current rsi is 42.12. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Relmada Therapeutics Inc Daily Relative Strength Index (RSI) ChartRelmada Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Relmada Therapeutics Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Relmada price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
Relmada Therapeutics Inc Daily Stochastic Oscillator ChartRelmada Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Relmada Therapeutics Inc. The current cci is -26.39493168.

Relmada Therapeutics Inc Daily Commodity Channel Index (CCI) ChartRelmada Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Relmada Therapeutics Inc. The current cmo is -7.60547542.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Relmada Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartRelmada Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Relmada Therapeutics Inc. The current willr is -73.46938776.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Relmada is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Relmada Therapeutics Inc Daily Williams %R ChartRelmada Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Relmada Therapeutics Inc.

Relmada Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Relmada Therapeutics Inc. The current atr is 0.1439414.

Relmada Therapeutics Inc Daily Average True Range (ATR) ChartRelmada Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Relmada Therapeutics Inc. The current obv is -25,473,144.

Relmada Therapeutics Inc Daily On-Balance Volume (OBV) ChartRelmada Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Relmada Therapeutics Inc. The current mfi is 28.29.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Relmada Therapeutics Inc Daily Money Flow Index (MFI) ChartRelmada Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Relmada Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-02-13RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-15MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-16STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-20CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-21RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-27CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-28WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-01BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-04RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-17MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-04-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-25BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-15STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-05-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-05-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-05-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-24MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-05-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-30RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-31MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-06-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-06-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-06-05STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-06-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-10STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-06-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-24MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-06-26MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-07-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-02STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

Relmada Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Relmada Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.117
Ma 20Greater thanMa 503.015
Ma 50Greater thanMa 1003.277
Ma 100Greater thanMa 2004.261
OpenGreater thanClose3.000
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Relmada with someone you think should read this too:
  • Are you bullish or bearish on Relmada? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Relmada? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Relmada Therapeutics Inc

I send you an email if I find something interesting about Relmada Therapeutics Inc.


Stay informed about Relmada Therapeutics Inc.

Receive notifications about Relmada Therapeutics Inc in your mailbox!